Of course, more in vitro and in vivo studies are needed to verify the relationship and mechanism between HMOX1, MMP9, and TNFRSF11B and anti-PD1/PD-L1 therapy in HCC. Here, HMOX1 is linked to hepatocellular carcinoma.